Did you know that the U.S. NASH Action Plan is the first and only national action plan created to address the growing epidemic of NASH? In 2021, GLI NASH Council partners...
As the world continues to gain a better understanding of COVID-19 and ever present and new variants, Global Liver Institute wants to ensure that we are here to continue to guide, educate, and...
(Washington, D.C., May 3, 2022) – Global Liver Institute (GLI), a premier patient-led liver health nonprofit operating globally, is deeply concerned by the draft opinion published...
(Washington, D.C., April 29, 2022) – As leaders in the liver cancer community, Global Liver Institute and their Liver Cancers team expresses our gratitude and recognizes Dr. Ned Sharpless and...
Welcome to the very first edition of Pediatric & Rare Liver Diseases News! As we expand our offerings for and about this community, Global Liver Institute is also committed to keeping...
Today, April 6, the members of the Liver Action Network (LAN) pledge our collective support for Living Donor Day to honor the donors, recipients, families and caregivers, and clinical teams that...
Transforming Global Consciousness of Liver Health through Education and Advocacy (Washington, D.C., March 30, 2022) – Global Liver Institute (GLI), a patient-led liver health nonprofit...
New Season, New Format: Striving to meet the needs of the expanding liver health- interested community for timely information on must-know events and news specific to our Council communities...
Interested in learning more? Check out what GLI’s President and CEO Donna Cryer, JD has to say on Season 3, Episode 12 of Surfing the NASH Tsunami here. Nonalcoholic steatohepatitis (NASH) has a...
Global Liver Institute Launches Final Nonalcoholic Steatohepatitis (NASH) Externally-Led Patient-Focused Drug Development Meeting Outcome Report (Washington, DC, Wednesday, March 9,...
Recent News
Global Liver Institute Acknowledges FDA Request for Further Studies as Obeticholic Acid Remains Available for PBC Patients(Washington, D.C. November 12, 2024) – Global Liver Institute (GLI) acknowledges the U.S. Food and Drug Administration’s (FDA) decision today to...
After elections, a lame-duck Congress will need to pass appropriations bills and hopefully “clear the decks” by passing long-awaited health reforms Members of Congress will return to Washington, DC, after the elections. Hopes remain for a productive November...
Uniting for Equity in Liver Cancer Care This month at GLI, we're excited to spotlight our Liver Cancer Program Director, Sarah Manes, as she dives into topics on advocacy, prevalence rates, risks, symptoms, treatment and survivorship for those affected with liver...
Innovation Sparks New Ideas at NORD’s Breakthrough Summit Collaborative Voices across Rare Disorders Represented during the FDA Innovation Hub Global Liver Institute’s (GLI) Program Director of Pediatric and Rare Liver Diseases, Kristin Hatcher,...
Screening for MASLD is Cost-Effective for PatientsEmerging research continues to shape our understanding of liver health, from cost-effective screening for high-risk MASLD patients to alarming rates of steatosis among young adults without a prior history of fatty...
